Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
51. |
ECCT/25/08/02 | MK-8527-010 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women. |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya 1. KEMRI CMR RCTP (Kisumu county) |
21-11-2025 |
View |
52. |
ECCT/24/10/06 | A5409 A Phase 2, Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB) |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. KEMRI/WRP CRS (Kericho county) |
18-11-2025 |
View |
53. |
ECCT/25/04/04 | LIMIT A Low INR to Minimize bleeding with mechanical valves Trial (LIMIT) |
Principal Investigator(s) 1. Anthony KIBUKA Gikonyo Site(s) in Kenya The Karen Hospital |
12-11-2025 |
View |
54. |
ECCT/25/07/05 | Cabotegravir + Rilpivirine Lon A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studie |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. Moi University Clinical Research Centre (Elgeyo/Marakwet county) 3. KEMRI-WRP (Kericho county) 4. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
31-10-2025 |
View |
55. |
ECCT/25/07/06 | SASI Randomized Controlled Trial of Surfactant Administered via Supraglottic Airway Device (SALSA) Compared to Endotracheal Tube (InSurE) on Survival without Mechanical Ventilation in Preterm Neonates with Respiratory Distress Syndrome in Sub-Saharan Africa |
Principal Investigator(s) 1. Mary Waiyego Kariuki Site(s) in Kenya Kenyatta national Hospital |
31-10-2025 |
View |
56. |
ECCT/25/03/03 | ALIM STUDY Evaluating the safety and efficacy of Imatinib in combination with Artemether and Lumefantrine for the treatment of Uncomplicated Malaria: a three-part trial. |
Principal Investigator(s) 1. Dr. QUENTIN AWORI Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
27-10-2025 |
View |
57. |
ECCT/25/05/12 | SAFIRE A multicentre open-label, non-inferiority adaptive platform randomised controlled trial to evaluate the efficacy, safety, and tolerability of antimalarials for the treatment of uncomplicated malaria in the first trimester of pregnancy |
Principal Investigator(s) 1. Hellen Barsosio Site(s) in Kenya The Kenya Medical Research Institute (KEMRI), Centre for Global Health Research (CGHR) |
15-10-2025 |
View |
58. |
ECCT/25/05/05 | Hibiscus 2 - Site 252 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county) |
15-10-2025 |
View |
59. |
ECCT/25/05/13 | IVI CCV 002 A Phase II, randomized, controlled, age-descending study in adults and children to evaluate the safety and immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in cholera-endemic region |
Principal Investigator(s) 1. Walter Jaoko Site(s) in Kenya KAVI - Institute of Clinical Research, University of Nairobi |
07-10-2025 |
View |
60. |
ECCT/25/04/01 | PHASE 2/3 OF SII-TCV(B) A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS |
Principal Investigator(s) 1. WALTER OTIENO Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
07-10-2025 |
View |